Abstract: A breathing circuit contains a heating circuit (or heating wire) and a sensor, optionally a temperature sensor therein. The heating circuit (or heating wire), and/or the sensor is embedded within the conduit wall. Respiratory apparatuses containing such a breathing circuit, as well as methods of making such a breathing circuit are provided.

Abstract: In a pump assembly, the outer wall of the first inner-housing sidewall, the inner wall of the second inner-housing sidewall and the inner-housing top wall define a first chamber with a first opening, and the gas chamber of the first chamber is a sealed chamber collectively defined by the piston portion, the inner-housing top wall, the outer wall of the first inner-housing sidewall and the inner wall of the second inner-housing sidewall, so that the formation of the sealed chamber does not require an additional sealing ring. This thereby reduces the risk of gas leakage due to aging of the sealing ring. A container with contents discharge function provided by this disclosure can include the above pump assembly.

Abstract: The present invention relates to compounds of formula (I), a b (I), wherein R1 to R4 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: Disclosed is an application of allopurinol in the preparation of a drug for treating a cancer with high expression of a PAICS gene. Through screening by cell biology combined with animal experiments, and by bioinformatics analysis of gene expression of about 10,000 sample data from the TCGA database, It can be found and confirmed that allopurinol has significant anti-cancer and therapeutic effects on the cancer with abnormally high expression of the PAICS gene, including but not limited to, combined chemotherapy for cancer resistance, inhibition of cancer recurrence, improvement of prognosis survival rate, and the like.

Abstract: The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.

Abstract: Methods, systems, and software are provided for estimating a circulating tumor fraction for a test subject. Sequence reads are obtained from a panel-enriched sequencing reaction, including sequences for a first plurality of cfDNA fragments corresponding to probe sequences and a second plurality of cfDNA fragments not corresponding to probe sequences. Bin-level coverage ratios are determined from the sequences. Segments are formed by grouping adjacent bins based on similar coverage ratios and segment-level coverage ratios are determined based on bin-level coverage ratios for bins in the segment. For each simulated circulating tumor fraction in a plurality of circulating tumor fractions, segments are fitted to an integer copy state by identifying the integer copy state that best matches the segment-level coverage ratio.

Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3 and R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Abstract: Methods, systems, and software are provided for validating a copy number variation in a test subject. A first dataset is obtained comprising bin-level sequence ratios, segment-level sequence ratios and segment-level measures of dispersion. Bins representing regions of a human reference genome are determined from sequencing cell-free nucleic acids in a liquid biopsy sample and reference samples. Segments encompass subsets of adjacent bins, where segment-level sequence ratios and measures of dispersion are determined using bin-level sequence ratios. A copy number status annotation for a segment is validated by applying the first dataset to a plurality of filters comprising a measure of central tendency bin-level sequence ratio filter, a confidence filter, and a measure of central tendency-plus-deviation bin-level sequence ratio filter. When a filter is fired, the copy number status annotation of the segment is rejected; and when no filter is fired, the copy number status annotation of the segment is validated.

Abstract: A method for processing an account in a blockchain is provided. A freezing instruction with respect to a target account is received by a computer device. A freezing lock is generated by the computer device based on the received freezing instruction, the freezing lock including a freezing lock public key. A first freezing request is generated by the computer device based on the freezing instruction and the freezing lock public key. The first freezing request is transmitted by the computer device to a device in the blockchain. The first freezing request is a request based on which the target account is frozen by using the freezing lock and resource transfer of the target account is denied.

Abstract: A backlight source, a backlight module and a display device are provided. The backlight source includes a light source and a polarizer component, the light source is configured to emit light to the polarizer component, the polarizer component is configured to convert the light emitted from the light source into polarized light, and the polarizer component includes a birefringent material. The backlight source emits linearly polarized light by using the birefringent material.

Abstract: An extendable display screen structure, wherein a hollow part is provided on at least one side of a main base and two guiding components are symmetrically provided in the main base along two sides of the hollow part; at least one driving component is provided in the main base, and the driving component is provided with a power source to drive the driving component to move along the guiding component; at least one side of a flexible screen is wound around an outer periphery of at least one rotating shaft, the rotating shaft is rotatably disposed on a side of the driving component and forms linkage, the driving component, in linkage with the rotating shaft, moves along the guiding component out of the main base, whereby the flexible screen can be gradually released from the outer periphery of the rotating shaft to be extended outwards, and on the contrary, the driving component, in linkage with the rotating shaft, gradually moves into the main base, whereby the rotating shaft retracts the flexible screen.

Abstract: Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Abstract: An array substrate includes a slit electrode and a planar electrode disposed in each of sub-pixels on a base substrate. The planar electrode is located on a side of the slit electrode close to the base substrate, and the slit electrode includes a plurality of strip sub-electrodes. In each of the sub-pixels, an insulating layer is disposed between the slit electrode and the planar electrode, and a surface of the insulating layer facing away from the base substrate is provided with a groove at a position between at least one set of adjacent strip sub-electrodes in the plurality of strip sub-electrodes.

Abstract: A curable composition that includes a urethane multifunctional (meth)acrylate, an inorganic filler having a primary particle dimension of at least 200 nm, a photoinitiator system that can be activated by electromagnetic radiation in the range of 340-550 nm, a reactive diluent, and a reinforcing silica having a primary particle dimension of 100 nm of less. The sum of the absolute value of the difference in the refractive index of the filler and the refractive index of the composition cured without filler plus the birefringence of the filler is 0.054 or less, i.e. 0.054?|nfiller?nmatrix|+?filler, where nfiller is the refractive index of the filler, nmatrix is the refractive index of the composition cured without filler, and ?filler is the birefringence of the filler.

Abstract: Phase separated articles that include a matrix phase including an acrylate copolymer; and a silicone elastomer phase stably dispersed in the matrix phase. Methods of forming phase separated articles, and articles including phase separated articles are also included.

Abstract: This invention relates to new benzazepine carboxamide compounds of the formula wherein X and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR8 agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.

Abstract: T cell receptors that specifically recognize hAFP158 and methods of their use are provided.

Abstract: A communications terminal includes an antenna structure and a metallic frame that includes at least one slot. The antenna structure includes an NFC antenna and a non-NFC antenna. The NFC antenna includes an NFC radiator, a first filtering unit, and an NFC circuit, and the non-NFC antenna includes a non-NFC radiator, a second filtering unit, and a non-NFC circuit. The NFC radiator and the non-NFC radiator are formed by the metallic frame of the communications terminal, and the entire non-NFC radiator is in the NFC radiator. The NFC circuit is coupled to the NFC radiator by using the first filtering unit, the non-NFC circuit is coupled to the non-NFC radiator by using the second filtering unit, the first filtering unit is configured to filter out a non-NFC signal, and the second filtering unit is configured to filter out an NFC signal.